Seven major harms of hyperuricemia and the clinical status of Teijin gout (febuxostat)
Share
Hyperuricemia has risen to become the "fourth high" after the "three highs" (high blood pressure, high blood sugar, and high cholesterol), with a prevalence exceeding 13% in China . However, public awareness of it remains largely limited to "gout." In fact, long-term high uric acid is a "silent culprit" in causing damage to multiple organs throughout the body . This article, combining the latest guidelines and clinical research, provides an in-depth analysis of the systemic harms of hyperuricemia and dissects the core role and scientific application strategies of the original drug Teijin Gout (febuxostat) in its treatment.
I. Seven Major Dangers of Hyperuricemia: More Than Just Gout
1. Gouty arthritis: "Needle-point torture" for joints
Uric acid crystals deposited in the joint cavity can induce an acute inflammatory response , manifesting as sudden redness, swelling, heat, and pain in the joint, with 60% of cases first occurring in the first metatarsophalangeal joint. If serum uric acid is ≥600 μmol/L, the incidence of gout is as high as 30.5%; repeated attacks will lead to joint deformities and loss of function.
2. Kidney damage: The silent killer of kidney function
● Uric acid kidney stones : accounting for 5.1% of kidney stones in China, causing renal colic, hematuria and urinary tract obstruction.
● Chronic kidney disease : Uric acid crystals deposit in the renal interstitium, leading to interstitial nephritis and fibrosis. For every 60 μmol/L increase in serum uric acid, the risk of acute renal failure increases by 74%, and may eventually progress to uremia.
3. Cardiovascular disease: a "corrosive agent" for the vascular endothelium.
Uric acid damages vascular endothelial function and accelerates atherosclerosis through oxidative stress and inflammatory responses .
● For every 60 μmol/L increase in blood uric acid, the risk of coronary heart disease increases by 13% and the risk of hypertension increases by 23%.
● Heart failure patients with hyperuricemia have a significantly increased all-cause mortality rate.
4. Metabolic syndrome: a catalyst for metabolic disorders
High uric acid, obesity, and insulin resistance exacerbate each other:
● Inhibiting insulin signaling increases the risk of diabetes by 25% .
● Together with high blood lipids and high blood pressure, they form a "deadly quartet," increasing the risk of cardiovascular and cerebrovascular events.
5. Tissue damage: tophi and bone erosion
Long-term high uric acid levels can lead to the deposition of urate crystals under the skin, forming tophi (commonly found on the earlobes and fingers), which erode soft tissues and bone structures. In severe cases, surgical removal is required.
II. The therapeutic role of febuxostat: mechanism, advantages, and clinical positioning
▶ Mechanism of action: Precisely targets the "master switch" of uric acid synthesis.
Febuxostat is a selective xanthine oxidase (XO) inhibitor that blocks the conversion of xanthine to uric acid by binding to the molybdenum pterin active site of XO. Its unique advantages include:
● Dual-state inhibition : Simultaneously inhibits both oxidized and reduced XO, with an efficacy more than a thousand times that of allopurinol .
● Non-purine structure : Does not interfere with purine/pyrimidine metabolism, resulting in better safety.
▶ Three major treatment advantages establish its first-line status
1. Effectively lowers uric acid :
a. A daily dose of 80 mg can reduce serum uric acid by an average of 4.5 mg/dL, with significant effects within 2 weeks .
b. Long-term use (≥2 years) can reduce the size of gouty tophi by up to 30%.
2. Kidney-friendly :
a. It is excreted through both the liver and kidneys (49% excreted by the kidneys, 45% by the feces). No dose adjustment is required for patients with mild to moderate renal impairment .
b. Recommended as the first-line treatment for CKD stage 4-5 patients, with a maximum dose of 40 mg/day.
3. Applicability to special populations :
a. An alternative for those who are allergic to or intolerant to allergic to or intolerant to allergic to allergic to or intolerant to allergic to orergic ...
b. The HLA-B*5801 positivity rate is high in Asian populations (7.5%), and febuxostat can avoid the risk of allopurinol hypersensitivity reactions.
▶ Guideline Recommendations: Core Choices for Personalized Treatment
● Chinese guidelines (2019) : Febuxostat is recommended as a first-line drug for lowering uric acid in gout, starting at 20 mg/day and up to 80 mg/day.
● International Update 2025 :
For patients with excessive uric acid production (accounting for 60% of patients) or those with cardiovascular disease, febuxostat is the preferred treatment .
It is still safe to use in patients with renal insufficiency (eGFR < 30 mL/min).
III. Scientific Medication Strategies: Risk Mitigation and Efficacy Optimization
1. Dosage adjustment and target management
● Start with 40 mg/day, and recheck uric acid after 2 weeks. If the uric acid level is not up to standard (>360 μmol/L), increase the dose to 80 mg/day .
● Target values : <360 μmol/L for those without tophi, and <300 μmol/L for those with tophi/kidney damage.
2. Avoiding cardiovascular risk controversies
● Black box warning response : Based on the CARES study (cardiovascular mortality HR=1.34), use with caution in patients with ischemic heart disease or heart failure .
● New evidence supports the view that the risk is manageable for those without a history of myocardial infarction/stroke.
3. Prevention of gout attacks and management of adverse reactions
● Initial treatment period : Use colchicine (0.5 mg/day) or NSAIDs for 3-6 months to prevent metastatic attacks .
● Key monitoring areas : Liver function (check ALT monthly for the first 3 months), cardiovascular symptoms (seek medical attention promptly for chest pain/difficulty breathing).
Recommendations for the use of febuxostat in different renal function states
|
Renal function classification |
Dosage adjustment recommendations |
Precautions |
|
Mild to moderate insufficiency (eGFR ≥ 30) |
No dose adjustment required |
Regularly monitor eGFR and uric acid levels |
|
Severe deficiency (eGFR<30) |
Start with 20-40 mg/day |
Avoid using nephrotoxic drugs in combination |
|
Kidney transplant patients |
Replace azathioprine with mycophenolate mofetil |
Cyclosporine should be avoided (it increases uric acid levels). |
IV. Combined Treatment and Chronic Disease Management
1. New trends in drug combination therapy :
a. SGLT2 inhibitors (such as empagliflozin): adjuvant in lowering uric acid (reduction of 1.55 mg/dL), synergistically improving cardiac and renal outcomes.
b. Combination therapy with URAT1 inhibitors : Dotinurad promotes uricosuric excretion and is used in combination with febuxostat for refractory gout.
2. Lifelong Management Philosophy :
a. Drug treatment needs to be combined with strict lifestyle interventions : drink 2000 ml of water daily, limit high-purine foods, and abstain from alcohol .
b. Establish a joint decision-making model between doctors and patients : regularly monitor uric acid and cardiac and renal function, and dynamically adjust the treatment plan.
Hyperuricemia is an alarm bell for a systemic metabolic crisis, with harms far exceeding joint pain. Teijin Gout (febuxostat), with its potent uric acid-lowering properties, renal protective characteristics, and individualized dosage advantages, has become a cornerstone drug for gout treatment. However, medication is only one part of a systemic approach —only by combining lifestyle interventions, regular monitoring, and multidisciplinary collaboration can long-term management of uric acid levels be achieved.
🏆Asakusa Cosmetics provides you with
✔️ Authentic Trelagliptin Succinate Tablets
✔️ Hospital prescription
✔️ Online doctor consultation
✔️ Pharmacist's Medication Instructions
✔️ Comprehensive after-sales tracking service
⚠️ Friendly reminder: This article is for reference only. Please consult your doctor for specific medication advice.
----------------------------------------------------------------------------------------------------